BRPI1013222B8 - composição que consiste em uma fração isolada de goma mastique obtida de pistacia lentiscus l. - Google Patents

composição que consiste em uma fração isolada de goma mastique obtida de pistacia lentiscus l.

Info

Publication number
BRPI1013222B8
BRPI1013222B8 BRPI1013222A BRPI1013222A BRPI1013222B8 BR PI1013222 B8 BRPI1013222 B8 BR PI1013222B8 BR PI1013222 A BRPI1013222 A BR PI1013222A BR PI1013222 A BRPI1013222 A BR PI1013222A BR PI1013222 B8 BRPI1013222 B8 BR PI1013222B8
Authority
BR
Brazil
Prior art keywords
isolated fraction
composition consisting
gum mastic
pistacia lentiscus
mastic obtained
Prior art date
Application number
BRPI1013222A
Other languages
English (en)
Inventor
Amselem Shimon
Hazan Zadik
Original Assignee
Regenera Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenera Pharma Ltd filed Critical Regenera Pharma Ltd
Publication of BRPI1013222A2 publication Critical patent/BRPI1013222A2/pt
Publication of BRPI1013222B1 publication Critical patent/BRPI1013222B1/pt
Publication of BRPI1013222B8 publication Critical patent/BRPI1013222B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)

Abstract

fração isolada de goma de mastique e composição de mirceno polimérico a invenção refere-se a composições e formulações que compreendem mirceno polimérico. mais particularmente, a invenção refere-sea composições que compreendem uma fração isolada de mirceno polimérico em um carregador hidrofóbico que mantém a atividade biológica do polímero ativo.
BRPI1013222A 2009-03-04 2010-03-04 composição que consiste em uma fração isolada de goma mastique obtida de pistacia lentiscus l. BRPI1013222B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15721609P 2009-03-04 2009-03-04
US61/157,216 2009-03-04
PCT/IL2010/000184 WO2010100651A2 (en) 2009-03-04 2010-03-04 Compositions of polymeric myrcene

Publications (3)

Publication Number Publication Date
BRPI1013222A2 BRPI1013222A2 (pt) 2017-09-26
BRPI1013222B1 BRPI1013222B1 (pt) 2021-03-16
BRPI1013222B8 true BRPI1013222B8 (pt) 2021-05-25

Family

ID=42536397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013222A BRPI1013222B8 (pt) 2009-03-04 2010-03-04 composição que consiste em uma fração isolada de goma mastique obtida de pistacia lentiscus l.

Country Status (15)

Country Link
US (4) US8722105B2 (pt)
EP (2) EP3578191A1 (pt)
CN (2) CN105147759A (pt)
AU (1) AU2010220057C1 (pt)
BR (1) BRPI1013222B8 (pt)
CA (1) CA2754565C (pt)
DK (1) DK2403512T3 (pt)
EA (2) EA201492273A1 (pt)
ES (1) ES2739033T3 (pt)
HK (1) HK1218710A1 (pt)
HU (1) HUE045444T2 (pt)
IL (2) IL214923A (pt)
PL (1) PL2403512T3 (pt)
TR (1) TR201911270T4 (pt)
WO (1) WO2010100651A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene
ES2617875T3 (es) 2009-03-04 2017-06-20 Regenera Pharma Ltd. Usos terapéuticos de masilla de goma
WO2011051945A1 (en) * 2009-10-28 2011-05-05 Regenera Pharma Ltd. Therapeutic uses of oligomeric and polymeric monoterpenes
BR122019022461B1 (pt) * 2010-09-07 2022-03-15 Regenera Pharma Ltd Processo para preparar uma fração ácida isolada de goma mástique
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
WO2013011511A1 (en) 2011-07-18 2013-01-24 Mor Research Applications Ltd. A device for adjusting the intraocular pressure
CN102526163A (zh) * 2011-12-27 2012-07-04 浙江景岳堂药业有限公司 一种用于风痛灵中乳香和没药的提取方法
US20150246087A1 (en) * 2012-06-11 2015-09-03 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
US10053603B2 (en) 2014-04-02 2018-08-21 Kraton Polymers U.S. Llc Block copolymers containing a copolymer myrcene block
US9458362B2 (en) 2014-04-02 2016-10-04 Kraton Polymers U.S. Llc Adhesive compositions containing a block copolymer with polymyrcene
IL237621A0 (en) * 2015-03-08 2015-06-30 Regenera Pharma Ltd Use of isolated fractions of the gum goddess to treat optic neuropathy
CA2999820A1 (en) 2015-09-24 2017-03-30 Regenera Pharma Ltd. Compositions comprising triterpenoids
DK3352742T3 (da) 2015-09-24 2022-01-10 Regenera Pharma Ltd Præparater omfattende triterpenoider til behandling af Alzheimers sygdom og Parkinsons sygdom
US10548917B2 (en) * 2016-05-23 2020-02-04 Kaeco Group Inc. Supplement for the prevention and treatment of gastrointestinal distress in horses and other species
US11439676B2 (en) 2018-10-16 2022-09-13 Kaeco Group, Inc. Method for prevention or treating gastrointestinal distress in humans using mastic gum compositions
US11207333B2 (en) 2016-09-08 2021-12-28 Regenera Pharma Ltd. Compositions comprising triterpenoids and uses thereof for treating optic neuropathy
EP3509577A4 (en) * 2016-09-08 2020-04-08 Regenera Pharma Ltd. COMPOSITION WITH ACID EXTRACTS FROM RUBBER FITTING AND USES THEREOF FOR TREATING OPTICAL NEUROPATHY
IT201700016726A1 (it) * 2017-02-15 2018-08-15 Phytoitalia Srl Frazioni arricchite in terpeni esenti da politerpeni estratte dal mastice di chios, dispositivi cosmetici, nutraceutici e medici, e composizioni farmaceutiche che le contengono
WO2019170239A1 (en) 2018-03-08 2019-09-12 Phytoitalia Srl Terpene enriched fractions free from polyterpenes extracted from chios mastic gum and cosmetic, nutraceutical, medical devices and pharmaceutical compositions containing them
CN113056281B (zh) * 2018-11-01 2023-05-26 耶迪特普大学 用于治疗牛皮癣的药物及其生产方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374957A (en) 1981-10-29 1983-02-22 Michigan Molecular Institute Triblock polymers of a monovinyl aromatic compound and myrcene
US4564718A (en) 1984-08-14 1986-01-14 The University Of Manchester Institute Of Science And Technology Functionally terminated polymers from terpene monomers and their applications
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
JPS63179908A (ja) * 1987-01-22 1988-07-23 Japan Synthetic Rubber Co Ltd ミルセン重合体およびその製造方法
DE3820218A1 (de) 1988-06-14 1989-12-28 Osama L M Dr Med Dr Rer N Omer Phytotherapeutikum zur behandlung von depressivem syndrom
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5506406A (en) 1993-05-17 1996-04-09 Atomic Energy Corporation Of South Africa Ltd. Method and apparatus for determining the concentration of a heavy element in a rock face
US5759569A (en) 1995-01-10 1998-06-02 The Procter & Gamble Company Biodegradable articles made from certain trans-polymers and blends thereof with other biodegradable components
US5714007A (en) 1995-06-06 1998-02-03 David Sarnoff Research Center, Inc. Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
GR950100243A (el) 1995-06-28 1997-02-28 �. �����- �. ����� �.�.�. Χρησιμοποιηση της φυσικης μαστιχας χιου η του εξαγομενου εξ'αυτης φυσικου μαστιχελαιου η συνθετικων παραγωγων του για την παρασεκυη οδοντοκρεμας, οδοντικου διαλυματος, αποσμητικου στοματος, αντιηλιακων, προιοντων μαλλιων, καθως και καλλυντικων προιοντων.
JPH10130254A (ja) * 1996-11-01 1998-05-19 Jumoku Seiri Kinousei Butsushitsu Gijutsu Kenkyu Kumiai ジヒドロクマリン系化合物およびエストロゲン作用剤
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
GR1003541B (el) 1999-05-11 2001-03-07 Αντιμικροβιακη και αντιμυκητιακη δραση του εξαγομενου απο τα κλαδια, φυλλα και καρπο της μαστιχας χιου -pistacia lentiscus var chia-, μαστιχελαιου, για χρηση σε καλλυντικες, φαρμακευτικες και παραφαρμακευτικεσς εφαρμογες καθως και στην παραγωγη οδοντοτσι
GR1003550B (el) 1999-09-22 2001-03-13 Σταθερο παρασκευασμα ισοεξυλοναφθαζαρινων με πεντα- και τετρα-κυκλικα τριτερπενια, συστατικα φυτικων ελαιορητινων και κομμεων
US6623728B2 (en) 2000-06-30 2003-09-23 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
US7056491B2 (en) 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
GR1003868B (el) * 2001-02-06 2002-04-19 Lavipharm S.A. Αξιολογηση των επουλωτικων, αντιοξειδωτικων και κυτταροστατικων ιδιοτητων της μαστιχας και των συστατικων της, και οι εφαρμογες τους
JP2004518707A (ja) 2001-02-13 2004-06-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム カロテノイドを充填されたリポソーム
US6534548B1 (en) 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
AU2003241345A1 (en) 2002-05-01 2003-11-17 Lavipharm S.A. Use of mastic and its components for the control of microbial infections
JP2004083443A (ja) 2002-08-23 2004-03-18 Hideji Watanabe マスティックを用いた歯周病予防・治療用組成物及び歯周病予防・治療方法
US7232872B2 (en) 2002-12-20 2007-06-19 Exxonmobil Chemical Patents Inc. Polymerization processes
ATE469923T1 (de) 2002-12-20 2010-06-15 Exxonmobil Chem Patents Inc Polymere mit neuen sequenzverteilungen
US20050074509A1 (en) 2003-10-02 2005-04-07 Data Medica Padova S.P.A. Cancer treatment using natural plant products or essential oils extracted from some pistacia species or components
CA2548430A1 (en) 2003-12-08 2005-06-16 Kenneth John Falk Plant materials extraction method
JP4831488B2 (ja) 2004-03-04 2011-12-07 独立行政法人理化学研究所 アイソタクチック３，４−イソプレン系重合体
WO2005112967A2 (en) * 2004-05-19 2005-12-01 Balfour Marketing Corp. Anticancer activity of chios mastic gum
JP2008505685A (ja) 2004-07-06 2008-02-28 トランスファーマ メディカル リミテッド 経皮免疫処置用送達システム
EP1781235B1 (en) 2004-07-23 2013-12-25 Wholesome Life Science Co., Ltd. Anti-allergy activities of zingiber zerumbet (l.) smith
EP2263663A1 (en) 2004-11-13 2010-12-22 Metaproteomics, LLC Compositions comprising curcuminoids and either alpha or beta acids for use in the treatment of diabetes
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
US20070148187A1 (en) 2005-12-27 2007-06-28 Intact Enterprises, Inc. Mastic gum composition for use as a dietary supplement in humans and animals
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
ES2617875T3 (es) 2009-03-04 2017-06-20 Regenera Pharma Ltd. Usos terapéuticos de masilla de goma
EP3578191A1 (en) 2009-03-04 2019-12-11 Regenera Pharma Ltd. Compositions of polymeric myrcene

Also Published As

Publication number Publication date
ES2739033T3 (es) 2020-01-28
US10307449B2 (en) 2019-06-04
US20120039992A1 (en) 2012-02-16
CN102413834B (zh) 2016-11-09
TR201911270T4 (tr) 2019-08-21
EP2403512A2 (en) 2012-01-11
DK2403512T3 (da) 2019-07-22
EP3578191A1 (en) 2019-12-11
BRPI1013222A2 (pt) 2017-09-26
AU2010220057C1 (en) 2015-10-29
CN102413834A (zh) 2012-04-11
AU2010220057A1 (en) 2011-10-13
EA021833B1 (ru) 2015-09-30
US10806763B2 (en) 2020-10-20
WO2010100651A3 (en) 2010-10-28
US20170252387A1 (en) 2017-09-07
US20190255132A1 (en) 2019-08-22
IL214923A0 (en) 2011-11-30
PL2403512T3 (pl) 2019-10-31
AU2010220057B2 (en) 2015-04-02
US20140294928A1 (en) 2014-10-02
EA201492273A1 (ru) 2015-04-30
WO2010100651A4 (en) 2010-12-23
EA201190170A1 (ru) 2013-01-30
WO2010100651A2 (en) 2010-09-10
EP2403512B1 (en) 2019-05-15
IL248056A0 (en) 2016-11-30
HK1218710A1 (zh) 2017-03-10
BRPI1013222B1 (pt) 2021-03-16
IL214923A (en) 2016-10-31
CA2754565C (en) 2020-12-29
HUE045444T2 (hu) 2019-12-30
US9655938B2 (en) 2017-05-23
CN105147759A (zh) 2015-12-16
IL248056B (en) 2019-07-31
CA2754565A1 (en) 2010-09-10
US8722105B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
BRPI1013222B8 (pt) composição que consiste em uma fração isolada de goma mastique obtida de pistacia lentiscus l.
WO2010100650A3 (en) Therapeutic uses of mastic gum fractions
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
CO6571886A2 (es) Antagonistas de pcsk9
WO2010130666A3 (de) Geruchsinhibierende zusammensetzungen
BR112012019997A2 (pt) composições de cuidado oral
GT201200276A (es) Combinaciones de compuestos activos
BR112014016008A2 (pt) composição
WO2012068105A3 (en) Compositions and uses thereof in converting contaminants
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
MX2012012837A (es) Composiciones farmaceuticas y metodos para su elaboracion.
NZ702930A (en) Racecadotril liquid compositions
MY156963A (en) Ethanol compositions
BR112012032882A2 (pt) liberação aumentada de ingredientes lopofílicos de goma de mascar com hidrocoloides
AR093052A1 (es) Composicion para pastas dentales
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
BR112013008368A2 (pt) composição de polímero
PE20142325A1 (es) Composiciones derivadas de la quitosana
DOP2009000262A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
EA201492286A1 (ru) Производные растений в качестве масел-наполнителей и бионаполнителей в эластомерных композициях
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MY161460A (en) Elastomeric dental floss
BRPI0817127A2 (pt) sistema desinfetante de evaporação diferencial potencializada
RS54594B1 (en) FORMULATIONS FOR THE CONTROL OF OBESITY CONTAINING SACCHAROMICES BOULARDII AND SUPEROXIDE DISMUTASE
TR201005327A2 (tr) Sinerjik farmasötik formülasyonlar.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2764 DE 26-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.